The company will pay nearly $2.1 million to the liquidating trust for the now-bankrupt HDL in order to resolve outstanding debt from a former joint lab venture.
As part of a restructuring and cost reduction plan the firm also reduced the principle of its 2016 convertible note by about half.
The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
The firm will provide product enhancement and clinical lab services, including comprehensive tumor profiling using proprietary cell-based products and services.
The company reported drops in revenues for both its human health and environmental health units, blaming challenging market conditions for the decreases.
The company beat analysts' consensus estimates on both the top and bottom lines as its molecular diagnostics sales rose 9 percent at constant exchange rates.
The company said the diagnostics unit will be focused on reproductive health, diagnostics for emerging markets, and applied genomics.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
In November, the company said it was selling off its biomedical commercialization and marketing services business in order to focus on its diagnostic offerings.
The company has scaled back its headcount from a peak of 115 employees to about 100 staff members, primarily on the commercial side.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.